155158-75-1

Basic information

• Product Name: R-2-AMINO-2,3-DIMETHYL-BUTAN-1-OL
• Synonyms: R-2-AMINO-2,3-DIMETHYL-BUTAN-1-OL
• CAS NO: 155158-75-1
• Molecular Formula: C6H15NO
• Molecular Weight: 117.19
• Mol File: 155158-75-1.mol

Chemical Properties

• Boiling Point: 198.5±13.0 °C(Predicted)
• Appearance: /
• Density: 0.907±0.06 g/cm3(Predicted)
• PKA: 12.85±0.20(Predicted)
• CAS DataBase Reference: R-2-AMINO-2,3-DIMETHYL-BUTAN-1-OL(CAS DataBase Reference)
• NIST Chemistry Reference: R-2-AMINO-2,3-DIMETHYL-BUTAN-1-OL(155158-75-1)
• EPA Substance Registry System: R-2-AMINO-2,3-DIMETHYL-BUTAN-1-OL(155158-75-1)

Safety Data

• Hazardous Substances Data: 155158-75-1(Hazardous Substances Data)

Upstream product

• 90376-98-0 (+)-(R)-2-amino-2,3-dimethylbutanamide 
• 53940-82-2 (R)-2-amino-2,3-dimethylbutanoic acid 
• 4378-19-2 (S)-α-Methylvaline 

Downstream Products

• 956102-59-3 (2S)-2-isopropyl-2-methyl-1-((4-methyl-phenyl)sulfonyl)aziridine 

Relevant articles and documents

Synthesis of enantiomerically pure 2,2-disubstituted-2-amino-ethanols by dissolving metal reduction of a,a-disubstituted amino acid amides

Enantiomerically pure 2,2-disubstituted 2-amino-ethanols are prepared in 65 - 99% yield by reduction of a,a-disubstituted amino acid amides using liquid sodium metal in refluxing 1-propanol.

ANTIFUNGAL AGENTS

Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs,,as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

ANTIFUNGAL AGENTS

Novel derivatives of enfumafungin are disclosed herein, along with' their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and method of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating and/or preventing fungal infections and associated diseases and conditions.

ANTIFUNGAL AGENTS

Novel derivatives of enfumafungin are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antifungal agents and/or inhibitors of (l,3)-β-D-glucan synthase. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating, and/or preventing fungal infections and associated diseases and conditions.

(S)-N-(5-Chlorothiophene-2-sulfonyl)-β,β-diethylalaninol a Notch-1-sparing γ-secretase inhibitor

Accumulation of beta-amyloid (Aβ), produced by the proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretase, is widely believed to be associated with Alzheimer's disease (AD). Research around the high-throughput screening hit (S)-4-chlorophenylsulfonyl isoleucinol led to the identification of the Notch-1-sparing (9.5-fold) γ-secretase inhibitor (S)-N-(5-chlorothiophene-2-sulfonyl)-β,β-diethylalaninol 7.b.2 (Aβ 40/42 EC50 = 28 nM), which is efficacious in reduction of Aβ production in vivo.

ANTIFUNGAL AGENTS

The present invention relates to novel enfumafungin derivatives of Formula IV-IA and pharmaceutically acceptable salts thereof, their synthesis, and their use as inhibitorspf(r,3)-β-D-glucan synthase. The present compounds and pharmaceutically acceptable salts therp?τ, as WeILaS1Sy-pharmaceutical compositions comprising the present compounds and pharmaceuticalty acceptable salts thereof, are useful for treating or preventing antifungal infections and associated diseases and conditions.

Process for the preparation of enantiomerically enriched compounds

1. Process for the preparation of enantiomerically enriched amino aldehydes and amino alcohols, wherein a corresponding enantiomerically enriched amino nitrile is subjected to hydrogenation in the presence of hydrogen, a hydrogenation catalyst, preferably a Pd-catalyst and a mineral acid. For the preparation of an amino aldehyde hydrogen preferably is present at a hydrogen-pressure between 0.1 and 2 MPa, in particular between 0.5 and 1 MPa. The amino aldehyde preferably is isolated in the form of a chemically and configurationally stable derivative. For the preparation of an amino alcohol, preferably at least during part of the hydrogenation hydrogen is present at a hydrogen-pressure between 2 and 10 MPa, in particular between 4 and 6 MPa. In a preferred embodiment the hydrogen-pressure initially is between 0,5 and 2 MPa and subsequently, after most of the nitrile starting material is converted, the hydrogen pressure is increased to a value between 2 and 10 MPa. The enantiomerically enriched nitrile starting material may a.o. be prepared by enzymatic resolution, classical resolution, resolution via preferential crystallization, diastereomeric synthesis, catalytic asymmetric synthesis or dehydratation of amino acid amides.